In Brief This Week: US Department of Defense, PerkinElmer; Luminex; Source BioScience, Inverclyde Biologicals; Crescendo Bioscience; More | GenomeWeb

NEW YORK (GenomeWeb News) – The US Department of Defense said recently that PerkinElmer Genetics has been awarded a maximum $9.7 million modification exercising the second option year of a one-year base contract with four one-year option periods for newborn screening services. "The modification is a firm-fixed-price with economic-price-adjustment, indefinite-delivery/indefinite-quantity, performance-based service contract," according to DoD. May 6, 2014 is the performance completion date. PerkinElmer did not reply to a message seeking additional information.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.